Suppr超能文献

抗抑郁药度洛西汀与吡拉西坦在小鼠体内联合使用不会增强促智活性。

The Combination of Antidepressant Duloxetine with Piracetam in Mice does not Produce Enhancement of Nootropic Activity.

作者信息

Kale Pravin Popatrao, Addepalli Veeranjaneyulu, Sarkar Amrita, Patel Sonam, Savai Jay

机构信息

Department of Pharmacology, SPP SPTM, NMIMS University, India. ; Department of Pharmacology, Dr. Bhanuben Nanavati College of Pharmacy, Mumbai 400-056, India.

Department of Pharmacology, SPP SPTM, NMIMS University, India.

出版信息

Exp Neurobiol. 2014 Sep;23(3):224-30. doi: 10.5607/en.2014.23.3.224. Epub 2014 Sep 18.

Abstract

There is a strong association between depression and memory impairment. The present study aims to assess the nootropic activity of duloxetine and piracetam combination. Male Swiss Albino mice were divided randomly into 4 groups. Treatment of normal saline (10 ml/kg), duloxetine (10 mg/kg), piracetam (100 mg/kg), and duloxetine (5 mg/kg) plus piracetam (50 mg/kg) were given through intra-peritoneal route to group I-IV, respectively. Transfer latency in elevated plus maze (EPM) and time spent in target quadrant in Morris water maze (MWM) were recorded. Estimation of brain monoamines in hippocampus, cerebral cortex, and whole brain were done using HPLC with fluorescence detector. Piracetam treated group showed significant decrease in transfer latency in EPM and increase in time spent in target quadrant recorded in MWM. Combination treated group failed to produce statistically significant nootropic effect in both EPM and MWM. Combination treated group failed to increase brain monoamine levels when compared against duloxetine and piracetam treated groups, separately. But there was exception of significant increase in norepinephrine levels in hippocampi when compared against duloxetine treated group. Results indicate no cognitive benefits with piracetam plus duloxetine combination. These findings can be further probed with the aim of understanding the interaction between duloxetine and piracetam as a future endeavor.

摘要

抑郁症与记忆障碍之间存在密切关联。本研究旨在评估度洛西汀与吡拉西坦联合用药的益智活性。将雄性瑞士白化小鼠随机分为4组。分别向第I - IV组腹腔注射生理盐水(10 ml/kg)、度洛西汀(10 mg/kg)、吡拉西坦(100 mg/kg)以及度洛西汀(5 mg/kg)加吡拉西坦(50 mg/kg)。记录高架十字迷宫(EPM)中的转移潜伏期以及莫里斯水迷宫(MWM)中在目标象限所花费的时间。使用带荧光检测器的高效液相色谱法(HPLC)对海马体、大脑皮层和全脑中的脑单胺进行测定。吡拉西坦治疗组在EPM中的转移潜伏期显著降低,在MWM中记录到的目标象限停留时间增加。联合治疗组在EPM和MWM中均未产生具有统计学意义的益智作用。与度洛西汀和吡拉西坦治疗组分别相比,联合治疗组未能提高脑单胺水平。但与度洛西汀治疗组相比,海马体中去甲肾上腺素水平有显著升高,这是个例外。结果表明度洛西汀加吡拉西坦联合用药并无认知益处。作为未来的研究方向,这些发现可进一步深入探究,以了解度洛西汀与吡拉西坦之间的相互作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/16c7/4174613/32774b227ebd/en-23-224-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验